Mirati Forges Path Forward For Adagrasib In mNSCLC Despite Lukewarm Preliminary Early-Stage Data

 
• By Ayisha Sharma

The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.  

Two pairs of hands holding white paper lungs on teal background
There Are 25,000 Lung Cancer Patients In The US With A KRAS G12C Mutation • Source: Shutterstock

More from Anticancer

More from Therapy Areas